Get the Stockscreener App
2.65
2.57%
-0.07
OncoCyte Corporation stock is traded at $2.65, with a volume of 51,737.
It is down -2.57% in the last 24 hours and up +25.00% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$2.72
Open:
$2.78
24h Volume:
51,737
Relative Volume:
0.51
Market Cap:
$75.79M
Revenue:
$709.00K
Net Income/Loss:
$-43.14M
P/E Ratio:
-0.5837
EPS:
-4.54
Net Cash Flow:
$-20.35M
1W Performance:
+3.52%
1M Performance:
+25.00%
6M Performance:
-12.25%
1Y Performance:
-13.68%
1-Day Range:
$2.57
$2.79
1-Week Range:
$2.51
$2.8499
52-Week Range:
$1.922
$3.4799
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
Compare OCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.65 | 75.79M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Oncocyte secures $29.1 million to advance FDA assay - MSN
Broadwood Partners acquires OncoCyte shares worth $9.24 million - MSN
OncoCyte stock hits 52-week low at $1.92 amid market challenges - MSN
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million - MSN
Oncocyte corp CFO buys $200,000 in stock - MSN
Oncocyte corp CFO buys $200,000 in stock By Investing.com - Investing.com Canada
Oncocyte Corp CFO Acquires 97,561 Shares in Private Placement - TradingView
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million By Investing.com - Investing.com South Africa
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - The Manila Times
Exclusive: Oncocyte (OCX) CEO & CFO to Meet Top Investors at BTIG's Elite Healthcare Conference - StockTitan
Oncocyte Corp enters into securities purchase agreements - Medical Buyer
Broadwood Partners acquires OncoCyte shares worth $9.24 million By Investing.com - Investing.com Nigeria
Oncocyte Prices $29 Million Stock Offerings -February 10, 2025 at 12:41 pm EST - Marketscreener.com
Oncocyte prices $29.1M equity offering - MSN
Oncocyte Secures $29.1Mln Funding Led By Bio-Rad To Advance Transplant Diagnostics, Stock Down - Nasdaq
OncoCyte’s $29.1M Funding Through Securities Agreements - TipRanks
Oncocyte Prices $29.1 Million Equity Offering - The Manila Times
ForexTV | Small Business Resources - ForexTV.com
Oncocyte (OCX) Secures Game-Changing $29.1M Investment to Revolutionize Early Transplant Rejection Detection - StockTitan
Oncocyte corp investor Patrick Smith buys $1,839 in shares By Investing.com - Investing.com South Africa
Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN
Oncocyte Corporation (NASDAQ:OCX) Shares Rebounded 7.25% From Their Lows – But Can They Continue? - Marketing Sentinel
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock - Investing.com India
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock By Investing.com - Investing.com Australia
OncoCyte (STU:7OC0) PS Ratio : 47.04 (As of Jan. 15, 2025) - GuruFocus.com
OncoCyte Co. (NASDAQ:OCX) Shares Bought by Geode Capital Management LLC - Defense World
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte Corporation (NASDAQ: OCX) Enters Amendment to Lease Agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLCOn January 2, 2025, Oncocyte Corporation announced in a Form 8-K filing that it has entered into an Amendment to a - Defense World
Oncocyte Corp amends lease agreement, sets expiration date By Investing.com - Investing.com Nigeria
Oncocyte Corp amends lease agreement, sets expiration date - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - Markets Insider
Oncocyte names Dr. Paul Billings as Consulting CMO - Investing.com India
Oncocyte Taps Harvard-Trained Diagnostics Veteran Dr. Paul Billings as Chief Medical Officer - StockTitan
Medicare expands coverage for kidney transplant test By Investing.com - Investing.com Australia
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - The Manila Times
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):